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cardiac arrest: study protocol for a randomized
controlled trial
Glenn M Eastwood1,2,3, Antoine G Schneider4, Satoshi Suzuki5, Michael Bailey3, Rinaldo Bellomo1,6*,
for the CCC trial investigatorsAbstract
Background: Cardiac arrest causes ischaemic brain injury. Arterial carbon dioxide tension (PaCO2) is a major
determinant of cerebral blood flow. Thus, mild hypercapnia in the 24 h following cardiac arrest may increase
cerebral blood flow and attenuate such injury. We describe the Carbon Control and Cardiac Arrest (CCC) trial.
Methods/Design: The CCC trial is a pilot multicentre feasibility, safety and biological efficacy randomized
controlled trial recruiting adult cardiac arrest patients admitted to the intensive care unit after return of
spontaneous circulation. At admission, using concealed allocation, participants are randomized to 24 h of either
normocapnia (PaCO2 35 to 45 mmHg) or mild hypercapnia (PaCO2 50 to 55 mmHg). Key feasibility outcomes are
recruitment rate and protocol compliance rate. The primary biological efficacy and biological safety measures are
the between-groups difference in serum neuron-specific enolase and S100b protein levels at 24 h, 48 h and 72 h.
Secondary outcome measure include adverse events, in-hospital mortality, and neurological assessment at
6 months.
Discussion: The trial commenced in December 2012 and, when completed, will provide clinical evidence as to
whether targeting mild hypercapnia for 24 h following intensive care unit admission for cardiac arrest patients is
feasible and safe and whether it results in decreased concentrations of neurological injury biomarkers compared
with normocapnia. Trial results will also be used to determine whether a phase IIb study powered for survival at
90 days is feasible and justified.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12612000690853.
Keywords: cardiac arrest, hypercapnia, intensive care, normocapnia, randomized trial, resuscitationBackground
Cardiac arrest results in the immediate cessation of blood
flow, sudden unconsciousness and, without prompt return
of spontaneous circulation, irreversible brain injury within
minutes [1,2]. Blood flow following return of spontaneous
circulation, while vital to survival, also heralds the onset of
cerebral reperfusion injury [3]. For cardiac arrest survivors,
acute neurological injury exerts a profound effect on* Correspondence: rinaldo.bellomo@austin.org.au
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unless otherwise stated.immediate, short-term and long-term quality of life out-
comes [4,5]. Recent level I evidence has shown that the ap-
plication of therapeutic hypothermia does not afford the
previously accepted benefits of neurological protection or
reduction in mortality [6]. Despite best efforts, the mortality
outcomes for resuscitated cardiac arrest patients admitted
to the intensive care unit remain high [7] and, in Australia
and New Zealand, over the past decade intensive care unit
mortality has essentially remained unchanged at 46% in
2003 and 48% in 2012 [8]. Thus, identifying modifiable as-
pects of post-resuscitation care to provide cerebral protec-
tion remains of extreme importance.ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Eastwood et al. Trials  (2015) 16:135 Page 2 of 6Arterial carbon dioxide tension (PaCO2) may be a
modifiable component of patient care that might deliver
improved neurological outcomes. Mild hypercapnia in-
creases cerebral perfusion [9,10] is known to have anticon-
vulsant properties [11,12] as well as anti-inflammatory and
anti-oxidant effects [13]. However, optimal PaCO2 levels
during the early post-resuscitation period are currently
poorly defined. Nonetheless, retrospective cohort studies
have identified hypocapnia, both before admittance to
[13,14] and within the intensive care unit [15-19], as being
independently associated with worse neurological and mor-
tality outcomes in cardiac arrest patients. Recently, a retro-
spective observational study of 16,542 patients enrolled at
125 participating intensive care units in Australia and New
Zealand between 2000 and 2011 [18] found that, while hy-
percapnic patients had a similar mortality rate to normo-
capnic patients, they had a greater likelihood of being
discharged home. Such findings were independently con-
firmed in a study of 409 out-of-hospital cardiac arrest pa-
tients from 21 Finnish intensive care units between March
2010 and February 2011 [11], and supported by observa-
tions on cardiac arrest in children [20] and experimental
studies [21,22].
Therefore, mild hypercapnia during the 24 hours after
cardiac arrest might contribute to positive neurological
outcomes. Moreover, given that resuscitated cardiac ar-
rest patients admitted to the intensive care unit typically
receive mechanical ventilation, it should be feasible to
target specific PaCO2 levels. This article describes a
protocol for a pilot feasibility, safety and biological efficacy
multicentre randomized controlled trial of therapeutic hy-
percapnia after cardiac arrest: the Carbon Control after
Cardiac Arrest (CCC) trial.
Methods/Design
The CCC trial is a prospective pilot, feasibility, safety
and biological efficacy multicentre, randomized con-
trolled trial.
Feasibility outcome measures include screened:recruited
patient ratio, weekly recruitment rate, protocol adherence,
time from cardiac arrest to first intensive care unit arterial
blood gas analysis, separation in PaCO2 levels between
groups, and ability to obtain Glasgow Outcome Scale
(Extended) assessments at 6 months from the date of
randomization for survivors. Safety outcome measures
include adverse changes in serum concentrations of
neuron-specific enolase and S100b protein (at 24 h,
48 h and 72 h), incidence and types of cardiac
arrhythmia, adverse changes in acid-base values, oxy-
genation (mean arterial oxygen tension, fraction of in-
spired oxygen requirement, alveolar-arterial gradient,
positive end expiratory pressure requirements) or in
the findings of cardiac echocardiography or cerebral
computed tomography during the first 24 h afteradmission to the intensive care unit, occurrence of
cerebral edema or right ventricular failure, incidence
of acute kidney injury as estimated using ‘risk, injury,
failure, loss, end-stage’ renal disease (RIFLE) criteria,
need for continuous renal replacement therapy, and
liver failure.
The primary biological efficacy outcome measure is the
difference in serum concentrations of neuron-specific eno-
lase and S100b protein at 24 h, 48 h and 72 h after
randomization between the hypercapnia and the control
groups. Neuron-specific enolase (a cytoplasmic glycolytic
enzyme) and S100b (a calcium binding protein) are bio-
markers specific to the central nervous system [23,24].
Serum concentrations of neuron-specific enolase and
S100b increase in both the cerebrospinal fluid and blood
following a cardiac arrest. Both biomarkers are predictive of
neurological outcome rather than survival outcome for
resuscitated cardiac arrest patients [23,24]. Sustained ele-
vated concentrations of neuron-specific enolase and S100b
protein in the first 24 h to 72 h following cardiac arrest are
associated with poor neurological outcome [24,25]. Second-
ary efficacy outcome measures include date, time and vital
status at intensive care unit and hospital discharge and hos-
pital discharge destination as clinical outcomes. A summary
of the feasibility, safety and primary and secondary out-
comes is provided in Table 1.
Study setting and participants
The intensive care units of four tertiary hospitals in
Australia and New Zealand will participate in this trial.
The CCC trial participants have to satisfy the protocol-
defined inclusion and exclusion criteria.
Inclusion criteria
 Resuscitated non-traumatic in-hospital or out-of-
hospital cardiac arrest;
 Receiving mechanical ventilation;
 Admitted to intensive care unit.
Exclusion criteria
 Spontaneous ventilation;
 Death considered imminent;
 Clinical or radiological suspicion of raised
intracranial pressure or intracranial bleeding;
 Pregnant;
 Younger than 18 years;
 Severe chronic airflow limitation;
 Severe metabolic acidosis (pH < 7.1 and base excess
< −6 mmol/l) uncorrected within the first 2 h of
admission to intensive care unit;
 Transferred from another healthcare facility;
 Participation declined by the treating clinician.
Table 1 Primary and secondary outcomes of the CCC trial
Feasibility outcomes Screened:recruited patient ratio
Weekly recruitment rate
Time from cardiac arrest to first analysis of
arterial blood gas in intensive care unit
Separation in PaCO2 levels between groups
for feasibility
Protocol adherence
Safety outcomes Adverse changes in cerebral injury biomarkers
(at 24 h, 48 h, and 72 h)
Incidence and type of cardiac arrhythmias
Adverse changes in acid-base balance
Adverse changes in oxygenation (mean
arterial carbon dioxide tension, fraction of
inspired oxygen, alveolar-arterial gradient,
positive end expiratory pressure requirement)
Adverse findings of cardiac echocardiography
or cerebral computerized tomography
Occurrence of cerebral oedema or right
ventricular failure and incidence of acute
kidney injury as estimated using RIFLE (‘risk,
injury, failure, loss, end-stage’ renal disease)
criteria, need for renal replacement therapy or
liver failure
Primary biological
efficacy outcome
Difference in serum neuron-specific enolase
and S100b protein concentrations at 24 h,
48 h, and 72 h compared with baseline for
each group
Secondary outcomes Date, time and vital status at discharge from
intensive care unit and hospital and discharge
destination as clinical measures
Glasgow Outcome Scale (Extended) assessed
at 6 months from date of randomization for
survivors, as a neurological assessment
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Randomization to either group will be performed using
sealed opaque envelopes with permuted blocks of ran-
dom sizes (block sizes 2 to 6) in a 1:1 ratio. Clinicians
will be directed to target normocapnia (PaCO2 35 to
45 mmHg) or mild hypercapnia (PaCO2 50 to 55 mmHg)
for 24 h during mechanical ventilation for each partici-
pant from the time of randomization. At all four sites,
ventilation management, to adjust PaCO2 levels, will be
achieved using intensive care unit-performed arterial
blood gas analysis data assessed after adjustment to 37°C
(alpha-stat) and guided on a minute-by-minute basis by
end-tidal CO2 levels. After the 24 h intervention period,
the treating clinician will determine the target PaCO2
level for each participant as per usual care. All remaining
patient care decisions will be at the treating clinicians’
discretion. Blood samples will be centrifuged and iso-
lated serum will immediately be frozen to −80°C at each
participating site. Stored serum samples will then be
shipped to the coordinating hospital and sent for batch
analysis at a central laboratory in Melbourne, Victoria.Data collection and management
Trained research staff at each trial site will collect trial
related data using a paper-based case report form. Infor-
mation to be collected using the case report form is out-
lined in Table 2. Completed case report forms will be
sent to the principal investigator at the Austin Hospital,
and data will be collated and entered into a central trial
database. The trial investigators at the Austin Hospital,
Melbourne will develop and manage the trial database,
coordinate sample shipment and batch analysis and will
perform the data analysis.
Ethical issues and trial registration
The Austin Hospital Human Research Ethics Committee is
the lead ethics committee (approval: HREC/13/Austin/166;
previously H2012/04737) and has provided approval for the
Australian sites. Jurisdictional ethics committee approval
has been obtained from the Health and Disability Ethics
Committees, Ministry of Health, NZ (12/NTA/54) for the
New Zealand site. Because of the specific nature of the trial,
and the need to apply the intervention in a timely fashion,
the need for prior informed consent was waived by the hu-
man research ethics committee. At the earliest appropriate
time, the participant or their legal surrogate were
asked for delayed consent. The trial was prospectively
registered with the Australian New Zealand Clinical
Trials Registry (ACTRN12612000690853).
Statistical analysis
Trial profile
Flow of patients through the trial will be displayed in a
Consolidated Standards of Reporting Trials (CONSORT)
diagram. We will report the number of screened patients
who met study inclusion criteria and the number of pa-
tients included in the study. We will report the reasons
for exclusion of ineligible patients according to the pre-
defined inclusion and exclusion criteria, as listed. In
addition, we will report the number of patients enrolled
into the trial and the number of participants from whom
a full set of serum biomarker samples were obtained.
Statistical analysis procedures
The efficacy and safety of the intervention will be evalu-
ated on an intention-to-treat analysis of all eligible par-
ticipants randomized to the trial. A sample size of 50
participants with full serum biomarker samples (base-
line, 24 h, 48 h and 72 h) was deemed sufficient to allow
for a meaningful assessment of neurological biomarker
difference between groups and for safety and feasibility
outcomes. No imputation or assumptions will be made
for missing data. Normally distributed continuous data
will be reported as mean with standard deviation and
compared using Student’s t test or analysis of variance
(ANOVA). Non-normally distributed continuous data
Table 2 Variables recorded in the CCC trial case report
form
Baseline information Patient characteristics (age, sex,
comorbities)
Inclusion criteria and consent details
Date and time of hospital admission
Date and time of admission to
intensive care unit
APACHE II and III score on admission
and immunocompromised status
Date and time of randomization
Cardiac arrest characteristics Location (in or out of- hospital), date
and time of cardiac arrest
Bystander cardiopulmonary
resuscitation
Time (minutes) until emergency
responder arrival
Initial cardiac rhythm
Time of first defibrillation and
number of defibrillation episodes
Time of return of spontaneous
circulation
Total adrenaline dose
Suspected cause of cardiac arrest
(arrhythmic, hypoxic, ischaemic,
pulseless electrical activity)
Intensive care unit procedures
and ventilation management
Time of first arterial blood gas
measurement and number of arterial
blood gas measurements in first
24 h
Therapeutic hypothermia initiated
(yes or no)
Nutrition commenced (yes or no)
Coronary angiography in first 24 h
Bicarbonate infusion commenced in
first 24 h
Recurrent cardiac arrhythmia (yes or
no)
Need for extracorporeal membrane
oxygenation or renal replacement
therapy
Electroencephalography, computed
tomography of the brain or
echocardiography (yes and finding
or not performed) in first 24 h
Intravenous medication use
(fentanyl, midazolam, neuromuscular
blockage medication, midazolam,
morphine, propofol)
Duration of mechanical ventilation
Arterial blood gas data during first
36 h of intensive care unit care while
mechanically ventilated
Ventilation data during first 36 h of
intensive care unit care while
mechanically ventilated
Table 2 Variables recorded in the CCC trial case report
form (Continued)
Urinary and serum creatinine
concentrations while in the intensive
care unit
Clinical outcomes Date, time and vital status at
discharge from intensive care unit
Date, time and vital status at
discharge from hospital
Destination after discharge from
hospital
Feasibility measures Screened:recruited patient ratio and
weekly recruitment rate
Separation in PaCO2 levels between
groups
Time (minutes) from cardiac arrest to
first arterial blood gas analysis in
intensive care unit
Safety measures Occurrence of severe raised
intracranial pressure or right
ventricular failure, incidence of acute
kidney injury as estimated using
RIFLE (‘risk, injury, failure, loss, end-
stage’ renal disease) criteria and liver
failure
Neurological evaluation
measure
Glasgow Outcome Scale (Extended)
evaluation performed at 6 months
APACHE, Acute Physiology and Chronic Health Evaluation; PaCO2, arterial
carbon dioxide tension.
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compared using the Mann-Whitney U test or the Kruskal-
Wallis one way ANOVA. Where sufficient symmetry exists,
biomarker sample data for each participant for each time-
point will be compared with repeated measures ANOVA;
alternatively, non-parametric techniques will be employed.
Categorical data will be reported as number and percentage
and compared using chi-square or Fisher exact tests where
indicated. Unless otherwise stated, a two-sided P value of
0.05 will be used to indicate statistical significance. We will
also perform an adjusted analysis for key cardiac arrest or
baseline characteristics or intensive care unit management
imbalances. All analyses will be performed using SAS ver-
sion 9.3 (SAS Institute Inc., Cary, NC, USA).
Tables and figures
Planned tables are:
 Baseline characteristics, cardiac arrest characteristics
and intensive care unit procedures for the trial
participants overall and according to study group.
 Primary and secondary outcome measures.
Planned figures are:
 CONSORT-style diagram illustrating the flow of
patients through the trial.
Eastwood et al. Trials  (2015) 16:135 Page 5 of 6 PaCO2 levels for normocapnia and mild hypercapnia
group participants over the first 36 h following
enrolment.
 Serum neuron-specific enolase concentrations for
normocapnia and mild hypercapnia group participants
with a complete set of neurological injury biomarkers
(baseline, 24 h, 48 h, and 72 h).
 Serum S100b protein concentrations for
normocapnia and mild hypercapnia group
participants with a complete set of neurological
injury biomarkers (baseline, 24 h, 48 h, and 72 h).
Data and safety monitoring
No data monitoring committee was established for this
investigator-initiated clinical trial. The principal investi-
gator at each site will review safety data for the duration
of the trial. All adverse events and serious adverse events
linked with the study intervention will be reported to
the Austin Health Human Research Ethics Committee
within 24 h of study staff becoming aware of the event
and in accordance with institutional and jurisdictional
human research ethics committee requirements.
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Discussion
The study commenced recruitment on 6 December 2012
at the Austin Hospital, Melbourne, Australia as single-
centre trial. In October, 2013 the additional three par-
ticipating sites joined the CCC trial, following the receipt
of streamlined ethical approval, making this a multicen-
tre trial. It is estimated that participant recruitment will
be completed by November 2014 and final 6-month
neurological assessment completed in May, 2015.
The results of the CCC trial will provide preliminary
clinical evidence regarding the feasibility and safety of
targeting mild hypercapnia for 24 h following intensive
care unit admission for cardiac arrest patients. It will
also provide preliminary information on whether such
treatment leads to lower levels of neurological injury
biomarkers concentrations, compared with normocap-
nia. Such trial results will be used to determine whether
a phase IIb study is feasible, safe and justified.
Trial status
Recruitment is active.Abbreviations
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